Colorectal cancer and diabetes

Czech version

Authors: Š. Svačina
Authors‘ workplace: III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in: Vnitř Lék 2011; 57(4): 378-380
Category: 12th national Symposium diabetes, "Diabetes and Gastroenterology", Hradec Kralove, 4 to 5 June 2010

Overview

Colorectal carcinoma is a tumour with higher incidence in patients with type 2 diabetes and obesity. Recently, a slightly higher risk has also been shown in prediabetic states. The most important latest finding is that of a reduced risk in patients treated with metformin; there is a trend now to also prescribe metformin in patients with disturbed glucose tolerance or increased fasting glycaemia. Regular physical activity and reduced animal fat intake with increased intake of fruits and vegetables may help to prevent the disease. Pathogenesis may include changes to intestinal flora. The most important current preventive clinical measure is colonoscopy. Type 2 diabetes patients should be considered as a risk group and thus prevention should be targeted at these patients.

Key words:
metabolic syndrome – type 2 diabetes mellitus – colorectal cancer – prediabetes – metformin

Sources

1. Svačina Š et al. Metabolický syndrom. Praha: Triton 2006.

2. Svačina Š. Nádory ledvin, močového měchýře a prostaty u obezity a diabetu. Vnitř Lék 2008; 54: 464–467.

3. Svačina Š, Matoulek M, Svobodová Š et al. Nádory trávicího traktu a diabetes mellitus. Vnitř Lék 2004; 50: 386–391.

4. Hjalgrim H, Frisch M, Ekbom A et al. Cancer and diabetes – a follow-up study of two population-based cohorts of diabetic patients. J Intern Med 1997; 241: 471–475.

5. Jonasson JM, Ljung R, Talbäck M et al. Insulin glargine use and short-term incidence of malignancies – a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745–1754.

6. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766–1777.

7. Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732–1744.

8. Diabetologia 2010; 1. České vydání, výběr z časopisu.

9. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674–1685.

10. Garfinkel L. Overweight and cancer. Ann Intern Med 1985; 103: 1034–1036.

11. Ford ES. Body mass index and colon cancer in a national sample of adult US men and women. Am J Epidemiol 1999; 150: 390–398.

12. Hu FB, Giovannucci E. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999; 91: 542–547.

13. La Vecchia C, Negri E, Decarli A et al. Diabetes mellitus and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 1997; 6: 1007–1010.

14. Meyerhardt JA, Catalano PJ, Haller DG et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003; 21: 433–440.

15. Ren X, Zhang X, Zhang X et al. Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China. Public Health 2009; 123: 540–544.

16. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766–1777.

17. Zhou XH, Qiao Q, Zethelius B et al. DECODE Study Group. Diabetes, prediabetes and cancer mortality. Diabetologia 2010; 53: 1867–1876.

18. Noh GY, Hwang DY, Choi YH et al. Effect of diabetes mellitus on outcomes of colorectal cancer. J Korean Soc Coloproctology 2010; 26: 424–428.

19. Holcátová I, Svačina Š. Dieta v prevenci a léčbě nádorových onemocnění. In: Svačina Š (ed.). Klinická dietologie. Praha: Grada 2008: 265–277.

20. Tlaskalová-Hogenová H, Stěpánková R, Kozáková H et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011; 8: 110–120.